Visvanathan, Sudha
Boehringer Ingelheim (United States)
3 papers on CoChatORCID 0000-0002-1170-9272
Most cited papers
- Verified
Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study
Feagan, B. G., Sandborn, W. J., D'Haens, G., Panés, J., Kaser, A., Ferrante, M., Louis, E., Franchimont, D., Dewit, O., Seidler, U., et al. (2017) · The Lancet
Inflammatory Bowel DiseasePsoriasis: Treatment and Pathogenesis
Cited by 451
- Verified
Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study
Baeten, D., Østergaard, M., Wei, J. C.-C., Sieper, J., Järvinen, P., Tam, L.-S., Salvarani, C., Kim, T.-H., Solinger, A., Datsenko, Y., et al. (2018) · Annals of the Rheumatic Diseases
Spondyloarthritis Studies and TreatmentsPsoriasis: Treatment and Pathogenesis
Cited by 390
- Verified
Global skin gene expression analysis of early diffuse cutaneous systemic sclerosis shows a prominent innate and adaptive inflammatory profile
Skaug, B., Khanna, D., Swindell, W. R., Hinchcliff, M. E., Frech, T. M., Steen, V. D., Hant, F. N., Gordon, J. K., Shah, A. A., Zhu, L., et al. (2020) · Annals of the Rheumatic Diseases
Systemic Sclerosis and Related DiseasesDupuytren's Contracture and Treatments
Cited by 179
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free